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Metastatic Ewing sarcoma has a very poor prognosis and therefore new investigations into the biologic drivers of
metastatic progression are key to finding new therapeutic approaches. The tumor microenvironment is highly
dynamic, leading to exposure of different regions of a growing solid tumor to changes in oxygen and nutrient
availability. Tumor cells must adapt to such stress in order to survive and propagate. In the current study, we
investigate how Ewing sarcoma cells respond to the stress of growth factor deprivation and hypoxia. Our findings
reveal that serum deprivation leads to a reversible change in Ewing cell cytoskeletal phenotypes. Using an array of
migration and invasion techniques, including gelatin matrix degradation invadopodia assays, we show that
exposure of Ewing sarcoma cells to serum deprivation and hypoxia triggers enhanced migration, invadopodia
formation, matrix degradation and invasion. Further, these functional changes are accompanied by and dependent
on activation of Src kinase. Activation of Src, and the associated invasive cell phenotype, were blocked by
exposing hypoxia and serum-deprived cells to the Src inhibitor dasatinib. These results indicate that Ewing
sarcoma cells demonstrate significant plasticity in response to rapidly changing micro-environmental stresses that
can result from rapid tumor growth and from necrosis-causing therapies. In response to these stresses, Ewing
cells transition to a more migratory and invasive state and our data show that Src is an important mediator of this
stress response. Our data support exploration of clinically available Src inhibitors as adjuvant agents for metastasis
prevention in Ewing sarcoma.
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Ewing sarcoma is a tumor of the bone or soft tissue that is driven by
EWS-ETS fusion oncoproteins, most commonly EWS-FLI1. The
incidence of Ewing sarcoma peaks in adolescents and young adults
and most patients in this age group present with localized bone
tumors and no overt evidence of metastatic disease [1,2]. Treatment
for localized Ewing sarcoma has been intensified over the past two
decades and upfront, compressed cycles of alternating vincristine/
doxorubicin/cyclophosphamide and ifosfamide/etoposide is the
current standard of cared and has led to a significant improvement
in survival in this patient population [3]. However, for patients who
present with overt metastatic disease or who relapse following initial
therapy, survival estimates remain dismal. Common sites of Ewing
sarcoma metastasis are the lungs, bones and bone marrow and
metatastic spread can be detected at any time, including many yearsafter initial presentation [4,5]. Despite attempts to identify
biomarkers of aggressive disease, it is still not clear why some patients
never develop metastasis and others go on to relapse at distant sites
despite experiencing initial clinical remissions [6]. Therefore, an
improved understanding of the underlying biologic processes that
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therapies to prevent and treat progressive disease in this high-risk
population [2].
The development and progression of solid tumors is dependent on
both tumor cell autonomous factors, such as the presence of
oncogenic mutations, and on the contributions of the tumor
microenvironment. The tumor microenvironment includes the
collection of secreted factors and cells that support and surround
the tumor cells [7]. In addition, while a number of secreted factors
can locally alter cell signaling [8], a more overarching influence is the
impact of hypoxia or nutrient deprivation on tumor cell behavior.
These micro-environmental stresses occur when tumors outreach
their blood supply or experience a rapid loss in blood flow due to
surgery, radiation or rapid tumor shrinkage secondary to
chemotherapy-induced tumor necrosis. Previous reports have noted
that conditions of hypoxia alter the transcriptional signature of
EWS-FLI1 [9], highlighting the potential impact of local stresses on
Ewing sarcoma cell behavior.
Prior work in our lab demonstrated that Ewing cells have the
ability to alter the expression of a key cell surface receptor, CXCR4, in
a rapid, reversible manner in response to microenvironmental stress,
including hypoxia and growth factor deprivation [10]. The plasticity
in expression of this G-protein coupled receptor altered the ability of
cells to migrate toward the chemokine ligand CXCL12, also known as
SDF-1. Given the key observation that stress can rapidly and
dynamically alter the CXCR4 axis in Ewing sarcoma to promote
chemotactic migration and invasion, we postulated that
micro-environmental stress might also have other more global effects
on the tumor cells that could contribute to a migratory and/or
invasive phenotype. Cell migration and invasion are essential
components of the metastatic cascade and, therefore, elucidation of
the mechanisms by which these processes are induced in Ewing
sarcoma cells could provide novel therapeutic opportunities to
specifically prevent tumor metastasis. In this study, we therefore
sought to further explore the impact of micro-environmental stress on
Ewing sarcoma cells and to investigate the biologic mechanisms that
contribute to cell plasticity and emergence of migratory/invasive
phenotypes.
Materials and methods
Cell lines and culture
The Ewing sarcoma cell lines A673 (ATCC, Bethesda MD, USA)
and CHLA-25 (Children's Oncology Group, COGcell.org) were
cultured in RPMI-1640 media (Gibco, Grand Island, NY, USA) and
CHLA-10 (COGcell.org) in IMDM media (Gibco). Cell lines were
supplemented with 10% (A673, CHLA-25) or 20% (CHLA10) FBS
(Atlas Biologicals, Inc., Fort Collins, CO, USA) and 6 mM
L-glutamine (Life Technologies, Grand Island, NY, USA).
CHLA-10 cells were additionally supplemented with 1×
insulin-transferrin-selenium (Life Technologies, Grand Island, NY,
USA). HeLa (ATCC) and PANC1 (a kind gift from the laboratory of
Dr. Diane Simeone, Univeristy of Michigan, Ann Arbor, MI) cells
were also utilized as a control cell lines in some experiments and were
cultured in RPMI-1640 or DMEM, respectively, and supplemented
with 10% FBS and 6 mM L-glutamine. Standard cell cultures were
maintained in ambient conditions at 37°C. For hypoxia studies, cells
were incubated in consistent 1% O2 in an xVivo system (Biospherix,
Parish, NY) at 37°C and 5% CO2. Serum deprivation consisted of0% FBS containing media. All cell lines are routinely tested for
mycoplasma and confirmed to be negative. Cell lines in the lab have
also undergone STR profiling to ensure authenticity.
Reagents
Primary and conjugated antibodies used in these studies include
phalloidin (Alexa Fluor 488 and 350, Molecular Probes, Eugene, OR),
cortactin (4F11 Alexa Fluor 555 conjugate; Millipore, Temecula, CA),
p-Y416 Src (Life Technologies, Frederick, MD), and GAPDH (Cell
Signaling, Beverly, MA). Secondary antibodies for western blot analysis
included IRDye 800CW goat anti-rabbit and goat anti-mouse (LiCor,
Lincoln,NE).TGF-betawas purchased fromR&DSystems (Minneapolis,
MN) and was used at a concentration of 10 ng/mL. Vehicle control for
the TGF-beta treatment was 4 mM HCl in sterile water.
Migration and invasion assays
Real-time cell analysis (RTCA) of cell migration and invasion was
monitored using a CIM-plate 16 and xCELLigence DP System (Acea
Bioscience, Inc.). Cells were serum starved overnight in 0% FBS
containing media. For migration studies, 1×105 cells/well were placed
in the upper chamber of a CIM-16 plate and then the plate was
equilibrated for 30 minutes at room temperature. For migration
assays done with a combination of stresses, cells were serum-starved
and placed in either normoxic or hypoxic conditions overnight before
evaluation of migration. For invasion studies, 1×105 cells/well were
plated in the upper chamber of wells that had been previously coated
with 5% (v/v) Growth Factor Reduced Matrigel Matrix (diluted 1:20
in serum-free base media). Matrigel-coated plates were allowed to
equilibrate for 4 hours in an incubator at 37°C before the addition of
cells. Cells were allowed to invade for 30 hours.
Transwell assays were also performed to assess migration and
invasion. Briefly, after incubating cells (in conditions denoted in
individual experiments) for 24 hours for migration and 48 hours for
invasion, non-migrating/invading cells were gently removed from the
upper surface and inserts were stained (Crystal Violet Stain; 0.5%
crystal violet, 20% methanol), washed and cells that had migrated or
invaded were imaged by light microscopy.
Invadopodia assay
FITC-gelatin invadopodia/matrix degradation assays were per-
formed as previously described [11]. Briefly, chamber well glass slides
(Lab-Tek II, Thermo Fisher Scientific, Rochester, NY) were coated
with FITC-labeled gelatin (Oregon Green gelatin from pig skin, 488
conjugate, Molecular Probes, Eugene, OR). For invadopodia assays,
cells were treated in conditions as dictated and described in the
individual experiments and then placed on the FITC-gelatin coated
chamber slides for 12–24 hours. Cells were then fixed using 2.75%
paraformaldehyde for 30 minutes, stained via immunofluorescence
(see below) and imaged using standard confocal microscopy (see
details below) following slide mounting with ProLong Gold
Anti-Fade reagent (Molecular Probes, Eugene, OR).
Immunofluorescence
Following fixation, cells were washed in 1× PBS, permeabilized
using 0.5% triton × 100, and blocked with 5% goat serum at room
temperature for 30 minutes. Cells were again washed in 1× PBS prior
to incubating with primary antibodies in 1% goat serum overnight at
4°C. Staining for cortactin and phalloidin was performed for
visualizing invadopodia (see reagents above).
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A Nikon A-1 Spectral Confocal microscope (Microscopy and
Imaging Analysis Laboratory, University of Michigan, Ann Arbor,
MI) was used to obtain all confocal microscopy images using a 60×
water lens.
Western blot analysis
Western blot analysis was performed using the Biorad
Mini-PROTEAN Tetra system (Hercules, CA). Following transfer,
nitrocellulose membranes were blocked in 50/50 1×TBS/Odyssey
Blocking Buffer (LiCor, Lincoln, NE) for 1 hour. Membranes were
washed once in 1× TBST and then incubated (rocking) overnight at
4°C in primary antibody. Membranes were then washed three times
in 1×TBST for 5 minutes each wash and then placed exposed to a
1:10,000 dilution of secondary antibody (see reagents above) in 5%
milk/TBST for 1 hour at room temperature. The membrane was then
washed in 1×TBST two times and lastly in one 1×TBS wash for 5
minutes prior to scanning the membrane using the LiCor Imaging
system (LiCor, Lincoln, NE).
Cell proliferation
Standard MTS assays were used to measure cell proliferation. 5000
cells were seeded into 96 wells in at least triplicate per condition and
allowed to incubate for 48 hours. Following this, 20 μl of MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) in the presence of phenazine metho-
sulfate (PMS) was added to each well and allowed to incubate for 3
hours at 37°C in the dark. Plates were then read on a plate reader at a
wavelength of 490 nm.
Quantitative real-time PCR
Total RNA was extracted from cells at 70% to 80% confluency
using Quick-RNA MicroPrep (Zymo Research, Irvine, CA) and
cDNA was generated using iScript (Bio-Rad Laboratories, Inc.,
Hercules, CA). Quantitative real-time PCR (qRT-PCR) was
performed using universal SYBR-Green Supermix (BioRad) for
designed primers (Supplementary Table S1). Analysis was performed
in triplicate using the Light-Cycler 480 System (Roche Applied
Science, Indianapolis, IN) and average Cp values were normalized
relative to the housekeeping (HK) gene HPRT1.
Results
Serum deprivation and hypoxia result in enhanced cell migration
and invasion
To determine the impact of stress on Ewing cell behavior, we first
examined cells under conditions of serum deprivation (0% FBS
containing media, SFM). Figure 1A shows that significant changes in
the actin cytoskeleton were induced following serum withdrawal.
Immunofluorescence labeling of Ewing cells with conjugated
phalloidin revealed alterations in F-actin filament distribution in all
three cell lines following 24 hours in SFM. With this change in the
cell actin cytoskeleton noted, we next assessed whether this
morphologic change was accompanied by any functional changes in
cell behavior. When cells were subjected to stress (SFM, no gradient),
all three cell lines demonstrated enhanced migration through
transwell inserts compared to non-stressed controls (Figure 1B).
Further, these stressed cells also showed an enhanced capability to
invade through Matrigel (Figure 1C).As a tumor grows and expands, it eventually outreaches its blood
supply, leading to concurrent loss of nutrients and oxygen [7]. Prior
reports showed that exposure to hypoxia can induce Ewing sarcoma
cells to invade and form soft agar colonies more effectively [9]. Our
studies corroborated these prior invasion results and also demon-
strated that, like serum deprivation, hypoxic stress also induces both
migration and invasion (Figure 1D). Thus, Ewing sarcoma cells
demonstrate remarkable functional plasticity in response to
micro-environmental stress and stressed cells transition to a more
migratory and invasive cell state.
Changes in cell phenotype are not due to induction of classic
EMT mediators
In carcinomas, cells classically change their cell cytoskeleton and
migratory capabilities after undergoing epithelial-to-mesenchymal
transition (EMT) [12]. Sarcomas, however, generally lack e-cadherin
expression, do not undergo this transition and can even display
baseline expression of some “classic” EMT markers [13–15].
Although a classic EMT would not be expected to occur in Ewing
sarcoma cells, the morphologic and functional changes that we
observed under stress were reminiscent of an EMT-like process. We
therefore examined whether stressed Ewing sarcoma cells demon-
strated evidence of up-regulation of transcription factors that regulate
EMT, such as SNAIL (SNAI1, Figure 2A), SLUG (SNAI2,
Figure 2B) or the intermediate filament protein encoding gene
vimentin (VIM, Figure 2C). None of these markers showed a
statistically significant increase in either SFM (Figure 2A) or hypoxic
(Figure 2B) conditions confirming that stress-dependent changes in
Ewing sarcoma cells are regulated independently of an EMT-like
process. PANC1 or HeLa cells (established models of EMT
induction) [16–20] were included as positive controls for EMT and
showed the expected increase in EMT genes in response to TGF-beta.
Acute stress does not significantly alter cell proliferation
Transition of carcinoma cells to a more migratory state is often
accompanied by cell cycle arrest and reduced cell proliferation [21].
We therefore performed MTS assays to examine whether Ewing
sarcoma cells showed differential rates of proliferation under stressed
and unstressed conditions. Despite their clear switch to a more
migratory and invasive state, Ewing sarcoma cells continued to
proliferate at nearly equivalent rates for up to 48 hours (Figure 3).
Furthermore, these data confirm that the enhanced number of
migrated and invaded cells that was observed under both stresses
(Figure 1) was not due to enhanced cell proliferation.
Stress drives invadopodia formation and matrix degradation
Invadopodia are actin-rich membrane protrusions that serve as
lead-points for cell invasion due to their role as sites of matrix
metalloproteinase concentration and secretion. As reviewed elsewhere
[22], the induction and turnover of invadopodia structures in highly
complex and dynamic and involves the coordinated activities of
numerous positive and negative regulators. However, key molecules
regulating the formation and function of invadopodia include Src,
cortactin, fascin, Tks5, p53, and caldesmon [22]. Invadopodia
structures have been identified both in vitro and in vivo and their
contribution to matrix degradation is critical to the process of cell
invasion, both in vitro and in vivo [22–24]. Therefore, examining the
regulation of these structures can provide key insights into why some
tumors cells may be are primed to metastasize.
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Figure 1. Cell stress induces changes in the cell actin cytoskeleton and enhances cell migration and invasion. (A) Fixed cells previously
treated with either 10% FBS (FBS, left column) or 0% FBS (SFM, right column) were stained with DAPI (blue) and phalloidin (red) to
examine changes in the cell cytoskeletal structure upon stress. White scale bars represent 10 microns. (B) Cells (FBS versus SFM) were
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Figure 2. Changes in noted Ewing sarcoma cell migratory
phenotype are not due to engagement of a classic EMT signature
program. qRT-PCR was performed to analyze stressed (SFM,
serum free media or hypoxia, 1%O2) versus unstressed (FBS, 10%
fetal bovine serum or normoxia, 21% O2) A673 and CHLA-25 cells
for up-regulation of the classic EMT genes SNAIL1 (A), SLUG (B)
and Vimentin (C). Cells were treated with FBS versus SFM or with
21% O2 versus 1% O2 for 24 hours and fold change in expression
relative to control is reported for the genes listed. PANC1 (A and B)
or HeLa (C) cells treated with 10mg/mL TGF-beta for 48 hours were
included as positive controls for induction of each gene examined.
Original Cp values were normalized relative to the housekeeping
(HK) gene HPRT1. Asterisks (*) denote a p-value of b0.05.
*
*
*
*
B
A
Figure 3. Enhanced cell proliferation is not responsible for the
increase in the number of migratory/invasive cells. Standard MTS
assays were used to measure cell proliferation under (A) FBS
versus SFM and (B) 21% O2 versus 1% O2 conditions for a
time-span of 48 hours. Data is reported as average absorbance
read at 490 nm. Asterisks (*) denote a p-value of b0.05.
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cells to more effectively migrate and invade, we examined the impact
of stress on cell invadopodia formation and matrix degradation. In
order to examine this, we subjected cells to culture conditions with
and without stress and then applied the cells to FITC gelatin matrix
degradation assays as previously described [11]. In these assays, the
black (non-fluorescent) areas amongst the FITC (green)-labeled
gelatin matrix are points of degradation. As shown in Figure 4A (top),
in ambient conditions, CHLA-10 cells showed very little matrix
degradation. In contrast, when exposed to the single stress of eitherserum deprivation or hypoxia CHLA-10 cells started to demonstrate
small amounts of matrix degradation compared to ambient/
non-stressed controls (Figure 4A, middle). Moreover, exposure to
concurrent stresses led to a striking difference in matrix degradation
(Figure 4A bottom). Cortactin is an actin binding protein that
localizes to invadopodia, is critical for their function and is therefore
used as a marker of these actin-based invasive cell structures [25].
Immunofluorescent labeling of CHLA-10 cells under ambient and
stressed conditions with a conjugated cortactin antibody confirmed
the presence of punctate cortactin-labeled structures co-localizing
with the area of matrix degradation (Figure 4A, center and right).
This effect of combined hypoxia and serum deprivation leading to
enhanced matrix degradation and invadopodia formation was also
noted in two additional cell lines, A673 and CHLA-25 (Figure 4B).
Thus, exposure of Ewing sarcoma cells to micro-environmental stress
results in induction of invadopodia and enhanced matrix degradation,
critical initial steps in the process of cell invasion.
Stress mediated Src activation and invadopodia formation can
be blocked by dasatinib
Src kinase is activated by auto-phosphorylation at tyrosine 416 and
increased phosphorylation at this site has been described in a number
of cancers, including sarcomas [26,27]. Src is a key protein regulating
invadopodia formation and function [22,28,29]. This led us to
investigate whether Src was activated in stressed tumor cells. Indeed,
we found that Src phosphorylation at tyrosine 416 increased in Ewing
sarcoma cells following exposure to the dual stress of hypoxia and
SFM (Figure 5A), raising the possibility that inhibition of Src might
result in inhibition of stress-mediated invadopodia formation and
matrix degradation. Dasatinib is a clinically available oral tyrosine
CHLA10
FB
S
21
%
O
2
SF
M
21
%
O
2
FB
S
1%
O
2
SF
M
1%
 O
2
gelatin cortactin gelatin/cortactin
A A673 CHLA-25
gelatin/cortactin
FB
S
21
%
O
2
S F
M
1%
O
2
B
Figure 4. Application of dual stress drives Ewing sarcoma matrix degradation capabilities. Representative images of FITC gelatin matrix
degradation assays in (A) CHLA10 cells when exposed to no stress (top panels), single stresses (middle panels) or combined serum
deprivation (SFM) and hypoxia (1% O2, bottom panels) for 24 hours. Corresponding cell staining for cortactin (red) is included as a marker
for punctate invadopodia structures. Black “holes” in the green gelatin represent areas of degradation. (B) Representative images of
gelatin degradation in A673 and CHLA25 cells in unstressed (FBS, 21% O2) versus dual stress (SFM and 1% O2) conditions are shown in
the top two panel rows. Bottom panels are magnified images of the dual stress condition with the cortactin overlay included to
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leukemia given its ability to target Abl in this Bcr-Abl fusion protein
driven malignancy [30]. However, dasatinib is a dual tyrosine kinase
inhibitor, and is also a potent ATP-competitive inhibitor of Src
tyrosine kinase [31]. While other in vitro Src inhibitors such as PP2
and SU6656 are commercially available, we chose to test dasatinib as
the Src inhibitor for our studies given its immediate clinical
applicability. The dose of dasatinib used in these studies was based
on previously reported data demonstrating Src inhibition at
nanomolar, sub-cytotoxic concentrations [32] and this effect was
confirmed in our cells. As shown, exposure of stressed cells to 50 nM
dasatinib successfully blocked stress induced Src kinase phosphory-
lation at tyrosine 416 (Figure 5B).
Next, we questioned whether this dasatinib-mediated inhibition of
Src activation could block stress-enhanced cell migration in Ewing
sarcoma. Dasatinib and DMSO vehicle treated cells were exposed to
dual stress and subjected to real-time monitoring of cell migration.
Exposure to dasatinib resulted in a marked inhibition of cell
migration over time (Figure 5C).
Finally, we assessed whether dasatinib could also inhibit
stress-enhanced matrix degradation and observed that inhibition of
Src kinase activation could indeed effectively block matrix degrada-
tion (Figure 6A). Significantly, however, following wash-out of
dasatinib, stressed CHLA10 cells rapidly recovered and even
augmented their ability to induce matrix degradation (Figure 6B).Altogether, these data highlight the key role of Src kinase in
stress-mediated migration and invasion in Ewing sarcoma, as
summarized in Figure 6C.
Discussion
Enhanced migratory and invasive capabilities are essential for cancer
cells to acquire the ability to metastasize. While carcinomas (epithelial
derived cancers) can acquire these phenotypes via signaling regulating
epithelial-to-mesenchymal transitions [12], sarcomas typically do not
follow this pattern, as they are already phenotypically “mesenchymal”.
However, not all sarcoma cells are primed to metastasize. The triggers
fueling the transition of sarcoma cells to a more aggressive state are
still not fully understood. In this study, we have demonstrated a
means of priming Ewing sarcoma cells to be more motile and invasive
by application of micro-environmental stress in the form of hypoxia
and/or serum deprivation. Clinically, these are very relevant stresses,
as with upfront therapy (chemotherapy, radiation, or surgery), tumors
are acutely exposed to changes in both oxygen and nutrient
availability via direct or indirect changes in tumor vasculature
resulting from these therapies. Ewing sarcoma tumors are highly
vascular and are therefore susceptible to such insults [33,34].
The concept of cellular plasticity in the context of tumor
heterogeneity is critical to finding better ways to prevent or treat
sarcoma metastasis [35–37]. Subsets of cells within a bulk tumor
respond differently to insults such as drugs, cytokines secreted by
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mechanism of therapy resistance. The tumor micro-environment can,
in fact, manipulate sub-populations of tumor cells to behave in either
more aggressive or dormant fashions [35]. Many prior studies of
Ewing sarcoma have largely focused on inter-tumoral rather than
intra-tumoral variances in cell behavior [6,38,39]. However, more
recently, evidence has surfaced revealing the truly heterogeneous
composition of Ewing sarcoma tumor cells within individual tumors
and cell lines [40,41]. We have demonstrated that acute,
stress-induced Src activation is one means by which subsets of
Ewing sarcoma cells can rapidly switch to a more aggressive state. Src
and invadopodia have been shown to be key regulators of metastasis
in other cancer types, such as melanoma [42], and our findings
support that this signaling axis could also play a seminal role in
inducing subsets of Ewing sarcoma cells to be primed to metastasize.
This is a very clinically relevant issue, as while it is suspected that the
majority of Ewing patients with localized tumors at diagnosis actually
do have micro-metastases, most of these patients are cured with
upfront, compressed cycles of chemotherapy. However, for patientsthat do progress to macro-metastatic disease or present with
metastatic disease at diagnosis, the clinical challenge is preventing
the vicious cycle of further spread of already established metastases, as
worsening metastatic disease is still the number one cause of patient
mortality.
Recently, the results of a Phase II clinical trial were published and
reported the impact of single agent dasatinib on advanced sarcoma
growth (including some cases of Ewing sarcoma) [43]. While slightly
higher doses of dasatinib have been reported to cause cell death/
apoptosis in sarcomas (such as osteosarcoma [44]), this trial did not
find clinical benefit in the use of single agent dasatinib to control
tumor growth in the majority of sarcomas examined. In the discussion
of these results, the authors importantly point out that the preclinical
data surrounding dasatinib was possibly more compelling for
prevention of tumor invasion and metastasis as opposed to its ability
to have cytotoxic effects on the tumor bulk. Our current results
support this hypothesis. Given the plasticity of Ewing sarcoma cells
under conditions of acute stress, we feel that further studies are
warranted to examine the role of Src inhibitors, such as dasatinib, as a
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invasion. It is possible that adding agents such as dasatinib during key
portions of therapy could help to prevent stress-mediated plasticity in
Ewing sarcoma and prevent cells from being primed to metastasize.
However, given our data demonstrating a rapid rebound in matrix
degradation capabilities following wash-out of dasatinib, such studies
would need to be mindful of the short half-life of dasatinib and to
ensure appropriate dosing intervals were applied to avoid significant
Src reactivation during therapy in patient tumors.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.06.008.
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